FDA has approved Moderna's COVID-19 vaccine for six-month-olds. The latest Food and Drug Administration authorization covers two new young age groups that can receive the medicine.
Charles Muro,age 13, celebrates being inoculated by a Nurse at Hartford Healthcares mass vaccination center at the Connecticut Convention Center in Hartford, Connecticut on May 13, 2021.
This latest achievement of the American pharmaceutical is quite helpful, especially for the parents who are always worried about their kids' health.
Ever since COVID-19 vaccines arrived, many experts have been quite doubtful about children receiving vaccines. But, Moderna's recent successful trials revealed that its COVID-19 drug is also efficient even with younger individuals.
Moderna COVID-19 Vaccine for 6-Month Olds?
According to Ars Technica's latest report, Moderna confirmed that it received FDA's authorization for its COVID-19 vaccine for children.
Maryland residents receive the Moderna COVID-19 vaccine through the Anne Arundel County Department of Health at a community COVID-19 vaccination clinic at the Metropolitan United Methodist Church March 23, 2021 in Severn, Maryland.
The two new age groups cover six months to two years old and two years old to six-year-old children. Thanks to the health agency's approval, more ineligible kids can now receive their vaccines.
"We are proud to share that we have initiated our EUA submission for authorization for our COVID-19 vaccine for young children," said Stephane Bancel, Moderna's CEO.
She added that their mRNA-1273 COVID-19 vaccine is safe for children's usage. Bancel claimed that Moderna's medicine would also be efficient in preventing COVID-19 infections in kids.
When it comes to effectiveness, Moderna is around 44% efficient in six months to two years old young people. On the other hand, it is about 37.5% efficient in two years olds to six years old children.
Moderna's New Bivalent Vaccine
Moderna seems to be pretty busy as the COVID-19 pandemic worsens in some parts of the globe. Aside from achieving FDA authorization for its two new young groups, the pharmaceutical company is also working on its new bivalent vaccine.
NPR reported that this new medicine could target both the original variant and the beta strain. Based on Moderna's preliminary findings, the new vaccine is effective since it can produce high levels of antibodies for months.
If you want to see further details about the new Moderna bivalent vaccine, you can visit this link.
Meanwhile, FDA authorized the new COVID-19 breath tests.
On the other hand, recent data revealed that the efficiency of Pfizer's 4th COVID-19 vaccine booster disappears after four months.
For more news updates about COVID-19 vaccines and other health topics, always keep your tabs open here at TechTimes.
Related Article: Updated Moderna COVID-19 Omicron Vaccine Distribution Date Now Confirmed
This article is owned by TechTimes
Written by: Griffin Davis
